Latest Licensing News

Generation Development Group (ASX, GDG) has reported a robust December quarter, with Funds Under Management surging across its core divisions, driven by strategic partnerships and acquisitions.

Noronex Limited’s ongoing 7,000m drilling program at its Powerline Copper Project in Namibia reveals further copper-silver mineralisation, reinforcing its geological model and partnership with South32.

Amplitude Energy has reported record quarterly production and revenue for Q2 FY26, alongside a dramatic reduction in net debt and the commencement of drilling for its East Coast Supply Project.

eMetals Limited has confirmed and extended a significant gold-in-soil anomaly at its Busia Gold Project in Uganda, highlighting promising early exploration results within a highly prospective greenstone belt.

Algorae Pharmaceuticals has locked in a $3 million revolving debt facility with ScotPac, providing flexible, non-dilutive funding to accelerate its commercial operations across Australia and New Zealand.

AdAlta Limited has aligned its AdCella manufacturing strategy with new US FDA guidelines, made a significant milestone payment to Shanghai Cell Therapy Group, and secured an additional R&D tax rebate, marking key progress in its cellular immunotherapy pipeline.

Audeara Ltd reported a strong Q2 FY26 with revenues up 274% year-on-year, securing key regulatory approval in China and expanding its global licensing footprint.

Firebrick Pharma has introduced its Nasodine Throat Spray in Singapore, marking its first international product launch and setting the stage for further global rollouts in 2026.

Mayfield Childcare Limited’s board has issued a Target’s Statement recommending shareholders reject Embark Early Education’s unsolicited takeover offer, citing undervaluation and significant risks. The offer, which includes a scrip or cash option, is seen as opportunistically timed amid Mayfield’s operational turnaround.

Neurizon Therapeutics has secured trademark protection for its NEURIZON® brand across major pharmaceutical markets, reinforcing its intellectual property strategy as it advances its lead drug candidate NUZ-001.

Atomo Diagnostics has locked in exclusive global rights to a novel liver function test that rapidly detects liver injury, expanding its footprint in point-of-care diagnostics. The test, delivered on Atomo’s Pascal platform, targets drug-induced liver injury and chronic liver conditions with significant commercial potential.

Neuren Pharmaceuticals has affirmed the material impact of Acadia’s projection that DAYBUE global net sales could reach approximately US$700 million by 2028, underpinning its royalty revenue outlook.